Full-Time

Bioinformatics Software Engineer

Posted on 3/27/2025

Tempus

Tempus

1,001-5,000 employees

Healthcare technology using AI for patient outcomes

Compensation Overview

$85k - $130k/yr

+ Incentive Compensation + Restricted Stock Units

Senior

Company Historically Provides H1B Sponsorship

Boston, MA, USA + 1 more

More locations: Chicago, IL, USA

Expected salary range is applicable if the role is performed from Illinois.

Category
Bioinformatics
Biology & Biotech
Software Engineering
Required Skills
Python
Software Testing
R
Machine Learning
Docker
AWS
Google Cloud Platform
Requirements
  • Must have completed a Ph.D. or a Masters with 3+ years of industry experience in Bioinformatics, Computational Biology, Cancer Biology, Genetics, Immunology, Molecular Biology, or Computer Science
  • Computational skills using Python and/or R
  • Experience with cloud-based systems such as AWS or Google Cloud Platform
  • Experience with container solutions such as Docker
  • Experience with common workflow languages such as Nextflow, snakemake, etc.
  • Experience interfacing with both scientific and engineering teams
  • Experience with software testing
  • Demonstrated effective communication and presentation skills
  • Self-driven and works well in interdisciplinary teams
Responsibilities
  • Build and design production-scale bioinformatics pipelines using contemporary tools for processing and analyzing NGS data within cloud-based computing environment
  • Develop novel assays, algorithms, machine learning and statistical models to detect oncology related biomarkers from cell free next-generation sequencing (NGS) data
  • Conduct analyses applying deep genomic and epigenomic knowledge to derive key insights from large multi-modal datasets
  • Execute experiments to characterize performance and support various regulatory submissions.
  • Produce high quality and detailed documentation for all projects.
  • Communicate results with other scientific teams as well as product and bioinformatics leadership.
  • Collaborate with other scientists and engineers

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to assist physicians in making informed treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights, aiming to improve patient care and support drug development.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnerships with AstraZeneca and Pathos AI boost Tempus' oncology capabilities.
  • Acquisition of Deep 6 AI expands Tempus' healthcare network and data access.
  • Debt financing supports Tempus' growth and technological advancements in precision medicine.

What critics are saying

  • High debt from acquisitions may strain Tempus' financial resources.
  • Over-reliance on partnerships could limit Tempus' strategic control.
  • Expansion beyond oncology may dilute Tempus' core focus and expertise.

What makes Tempus unique

  • Tempus uses AI to analyze clinical and molecular data for precision medicine.
  • Their platform aids in personalized treatment decisions for cancer and other diseases.
  • Tempus collaborates with major pharmaceutical companies to enhance drug development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Pharmaceutical Business Review
Apr 25th, 2025
Tempus AI, AstraZeneca, and Pathos AI join forces on cancer care

Tempus AI has entered into strategic partnerships with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology.

Fierce Biotech
Apr 23rd, 2025
Tempus AI in line for $200M from AstraZeneca, Pathos deal to develop cancer model

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs.

Health Technology Insights
Apr 21st, 2025
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

Tempus AI, Inc, a technology company leading the adoption of AI to advance precision medicine and patient care, announced the launch of the Tempus Advisory Board.

SDBN
Apr 15th, 2025
Illumina teams up with Tempus to expand DNA profiling beyond cancer

Illumina teams up with Tempus to expand DNA profiling beyond cancer.

Life Care News
Mar 30th, 2025
Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

Tempus exhibits 4 abstracts at the 2025 American College of Cardiology Annual Meeting.

INACTIVE